N-酰基-N′-茄呢基哌嗪衍生物的合成及生物活性

以茄呢醇为起始原料和茄呢基哌嗪为关键中间体合成了 4个N 酰基 N′ 茄呢基哌嗪 ( 4a～ 4d) ,以及 2个含葡萄糖单元的N ( 2 全乙酰葡萄糖基苯甲酰基 ) N′ 茄呢基哌嗪 ( 5 )和N ( 2 葡萄糖基苯甲酰基 ) N′ 茄呢基哌嗪 ( 6) ,共 6个新茄呢基哌嗪衍生物 .其结构经元素分析 ,IR ,1HNMR和MS确证 .测试了化合物 4c ,5 ,6对三种人癌细胞 (Bel 740 2 ,KB ,HCT 8)的体外生理活性 ,初步结果表明化合物 6比 4c和 5对三种所测细胞有更好的抑制效果     

茄呢基胺-氮芥衍生物的合成

首次设计并制备了二种以茄呢基胺和茄呢基哌嗪为载体的新型氮芥衍生物.即以二 (2 氯乙基 )胺盐酸盐为原料与邻苯二甲酸酐反应,合成出含有抗肿瘤活性基团的化合物 2 { [二 ( 2 氯乙基 )氨基 ]羰基 }苯甲酸,然后在二环己基碳二亚胺存在下,分别与茄呢基胺和茄呢基哌嗪进行酰化反应,得到两种含茄呢基胺类基团的氮芥衍生物,其结构经元素分析,IR,1HNMR和MS确证.     

N-茄呢基谷氨酰胺类化合物的合成

在N,N 二环己基碳二酰亚胺存在下,N 苯甲酰 Nα 茄呢基 L 谷氨酰胺酸和N 羟基琥珀酰亚胺反应制成活化酯,然后分别与胺或者氨基酸甲酯盐酸盐反应制得3种新N 茄呢基谷氨酰胺类化合物.这些化合物的结构经IR、1HNMR、MS和元素分析确证.     

酰胺型茄呢醇衍生物的合成与生理活性

酰胺型茄呢醇衍生物的合成与生理活性;N-茄呢基酰胺;N-酰基-N′-茄呢基哌嗪;合成;生理活性     

N-茄呢基胺类糖酯化合物的合成及生理活性

在氢氧化钠和四丁基溴化铵存在下,将化合物2-N-茄呢基胺基苯甲酸(3)和N-茄呢基己二酰胺酸(6)分别与O-乙酰基溴代葡萄糖、O-乙酰基溴代半乳糖、O-乙酰基溴代乳糖和O-乙酰基溴代麦芽糖反应制得对应的糖酯4a～4d和7a～7d,由元素分析,IR,1H NMR和MS确证了8个新化合物的结构,并对其中6个化合物(4a,4d和7a～7d)在三种癌细胞模型上进行了一些初步体外生理活性的测试.     

茄呢基氮芥衍生物的合成及生理活性

茄呢基氮芥衍生物的合成及生理活性;氮芥;茄呢醇;合成;生理活性     

茄呢基胺类化合物的合成研究(Ⅰ)——N,N-二(酰氧基乙基)茄呢基胺的合成

茄呢基胺类化合物的合成研究(Ⅰ)——N;N-二(酰氧基乙基)茄呢基胺的合成     

N-酰基吡唑衍生物的合成与生物活性

N-酰基吡唑衍生物的合成与生物活性;拟除虫菊酯;1H吡唑衍生物;合成;生物活性     

N-茄呢基-N,N′-二(3,4-二甲氧基苄基)乙二胺的合成

癌症仍是需要攻克的医学难题之一. 虽然已有多种抗癌剂用于临床,但大多数抗癌剂是以细胞毒性来抑制癌细胞的繁殖,使用剂量受到限制,长期治疗还会产生毒副作用. 研究表明,N-茄呢基-N,N′-二(3,4-二甲氧基苄基)乙二胺(简称SDB-乙二胺)[1]具有优先作用于多种抗药性肿瘤的直接的细胞毒性,对几乎所有类型临床抗肿瘤药物具有增效作用,其中对抗生素类和生物碱类抗癌药物的增效尤为显著,如对其中的博莱霉素(争光霉素)、呱来霉素、磅霉素等,每毫升注射液含有3和10 μg的SDB-乙二胺,药效分别能提高47和130倍,对新制癌菌素(neocarzinostatin)也能提高2倍以上[2]. 与其他增效剂相比,SDB-乙二胺的增效作用具有定向细胞毒性,而本身完全没有细胞毒性,安全性好,可以连续使用,可减少抗癌剂的剂量,减轻毒副作用[3]. 因此,研究开发抗癌药物增效剂是癌症治疗的发展方向之一.     

N-茄呢基-N,N''''-二芳基乙二胺衍生物的合成与生理活性

以乙二胺，芳香醛和相应的卤代物为原料合成了N-茄呢基-N，N’-二（3，4-二甲氧基苄基）乙二胺（SBD-乙二胺）及三个新的衍生物．对L1210和CHO细胞初步的体外活性测试表明在SBD-乙二胺的仲氮上引入第四个取代基后，生成的衍生物对所测细胞的抑制活性提高，但对长春新碱的增效作用减弱．     

喹啉-多胺衍生物的合成及其活性评价

设计合成了13个喹啉-多胺衍生物,产物结构均经1H NMR,ESI-MS和元素分析确认.采用噻唑蓝(MTT)法测试了化合物对连二亚硫酸钠损伤肾上腺嗜铬细胞瘤(PC12)细胞的抑制作用,结果表明所有目标化合物对PC12细胞损伤均有较好的抑制作用,部分化合物优于尼莫地平,其中化合物T6和T7的活性最强,10μmol/L浓度下损伤抑制率分别为28.04%和27.58%.     

Synthesis and Biological Evaluation of Some Novel Isoxazole Derivatives

The reaction of 5‐amino‐3‐methylisoxazole ( 1 ) with formalin and secondary amines gave the corresponding Mannich bases 3 , 4 , 5 , 6 . Alkylation of isoxazole derivative 1 with Mannich bases hydrochloride gave unsubstituted isoxazolo[5,4‐b ]pyridine derivatives 8a , 8b via alkylation at position 4. Moreover, coupling reaction of 1 with different diazonium salts gave the corresponding mono and bisazo dyes of isoxazole derivative. The newly synthesized compounds were screened for their antitumor activity compared with 5‐fluorouracil as a well‐known cytotoxic agent using Ehrlich ascites carcinoma cells. Interestingly, the obtained results showed clearly that compounds 3 , 15 , 8b , 4 , 8a , and 5 exhibited high antitumor activity than 5‐fluorouracil.     

Synthesis and Biological Evaluation of Entecavir 4'-Ester Derivatives

Entecavir can significantly inhibit the replication of HBV-DNA, reduce the HBV-DNA level in blood se- rum. But suffering from low oral bioavailability, entecavir has low intestinal membrane permeability and poor meta- bolic stability. In this study, 12 different derivatives of entecavir 4＇-ester were regioselectively synthesized and their apical-to-basolateral permeabilities across Caco-2 cells and HBV-DNA inhibitory efficacies were evaluated. Most of the compounds showed high permeabilities across Caco-2 cells compared with entecavir, compounds 5b and 5e also exhibited comparable anti-HBV activities with that of entecavir, especially.     

新型紫杉烷类衍生物的制备及生物活性评价

多药耐药性问题是导致第一代紫杉烷药物在临床化疗失败的主要原因。本文对紫杉醇C7、C10、C14、C3′多个位点的取代基进行改造,针对合成的6个新型的紫杉烷化合物,在体外考察其对多药耐药肿瘤细胞株以及人结肠癌HCT-116干细胞的增殖抑制活性,实验结果表明6个化合物的抗多药耐药活性均优于紫杉醇。采用P-gp高表达的犬肾细胞MDCK-MDR1进一步研究高活性候选化合物JT-3与P-gp的相互作用。以此研发抗多药耐药型的新一代紫杉烷类药物,对开发扩大抗癌新适应症的新一代紫杉烷类抗癌药意义重大。     

Synthesis of New Tetrazole Derivatives and Their Biological Evaluation

Russian Journal of General Chemistry - An operationally simple and efficient method of synthesis of novel 1,5-disubstituted tetrazoles with high yields from easily accessible...     

Synthesis,Docking and Biological Evaluation of Isoquinolonic Acid Derivatives

A series of isoquinolonic acid derivatives（4a-4o） was synthesized via one-pot synthesis for their anti-tumor activity. The structures of all the targeted compounds were confirmed by IH nuclear magnetic resonance （IH NMR） spectrometry and mass spectrometry（MS）. The anti-tumor activities of compounds 4a-4o against MG63（human osteosarcoma cells） and B16-F10（mouse melanoma cells） were examined. To evaluate the antitumor effect of the as-synthesized compounds, we compared the half maximal inhibitory concentration（1C50） of compounds 4a--4o to that of camptothecin（CPT） which appeared to be active against a broad range of human cancers. Among all the compounds, compound 41 shows the most potent biological activity against MG63 cells[IC50=（2.16i0.26） μmol/L] and B16-F10 cells[IC50=（6.95±0.24）μmol/L], thus providing useful information for the antitumor activity and potential practical use of isoquinolonic acid compounds. In addition, we screened out an efficient compound（41） that shows potential inhibit activity against Topoisomerase 1（Topo 1） by docking simulation.     

Synthesis and Biological Activity Evaluation of Coumarin-3-Carboxamide Derivatives

A series of novel coumarin-3-carboxamide derivatives were designed and synthesized to evaluate their biological activities. The compounds showed little to no activity against gram-positive and gram-negative bacteria but specifically showed potential to inhibit the growth of cancer cells. In particular, among the tested compounds, 4-fluoro and 2,5-difluoro benzamide derivatives (14b and 14e, respectively) were found to be the most potent derivatives against HepG2 cancer cell lines (IC₅₀ = 2.62–4.85 μM) and HeLa cancer cell lines (IC₅₀ = 0.39–0.75 μM). The activities of these two compounds were comparable to that of the positive control doxorubicin; especially, 4-flurobenzamide derivative (14b) exhibited low cytotoxic activity against LLC-MK2 normal cell lines, with IC₅₀ more than 100 μM. The molecular docking study of the synthesized compounds revealed the binding to the active site of the CK2 enzyme, indicating that the presence of the benzamide functionality is an important feature for anticancer activity.     

Bicyclic Isoxazoline Derivatives: Synthesis and Evaluation of Biological Activity

The application of non-planar scaffolds in drug design allows for the enlargement of the chemical space, and for the construction of molecules that have more effective target–ligand interactions or are less prone to the development of resistance. Among the works of the last decade, a literature search revealed spirothiazamenthane, which has served as a lead in the development of derivatives active against resistant viral strains. In this work, we studied the novel molecular scaffold, which resembles spirothiazamenthane, but combines isoxazoline as a heterocycle and cyclooctane ring as a hydrophobic part of the structure. The synthesis of new 3-nitro- and 3-aminoisoxazolines containing spiro-fused or 1,2-annelated cyclooctane fragments was achieved by employing 1,3-dipolar cycloaddition of 3-nitro-4,5-dihydroisoxazol-4-ol 2-oxide or tetranitromethane-derived alkyl nitronates with non-activated alkenes. A series of spiro-sulfonamides was obtained by the reaction of 3-aminoisoxazoline containing a spiro-fused cyclooctane residue with sulfonyl chlorides. Preliminary screening of the compounds for antiviral, antibacterial, antifungal and antiproliferative properties in vitro revealed 1-oxa-2-azaspiro[4.7]dodec-2-en-3-amine and 3a,4,5,6,7,8,9,9a-octahydrocycloocta[d]isoxazol-3-amine with activity against the influenza A/Puerto Rico/8/34 (H1N1) virus in the submicromolar range, and high values of selectivity index. Further study of the mechanism of the antiviral action of these compounds, and the synthesis of their analogues, is likely to identify new agents against resistant viral strains.